Nausea zonisamide

The most commonly observed adverse events associated with the use of zonisamide were agitation/irritability, anorexia, dizziness, headache, nausea, and somnolence. 

In a double-bUnd, placebo-controUed, add-on, randomized trial of zonisamide 400 mg/day in 203 patients over 14 years of age with refractory partial-onset seizures, the response rate was 42% (3). The most common treatment-emergent adverse events were somnolence, anorexia, rhinitis, dizziness, nausea or vomiting, ataxia, fatigue, and headache. With zonisamide, 22% of the patients lost over 2.3 kg compared with 10% on placebo. 

In the first study, 25 subjects had treatment-emergent adverse effects. Those that were considered to be possibly or probably related to zonisamide were fatigue (n = 2), abdominal pain (n = 2), and weakness, dry lips, nausea, anorexia, oral paresthesia, and back pain (one each). In the second study, 21 subjects had treatment-emergent adverse effects and those that were considered to be possibly or probably related to zonisamide were dizziness ( = 3), nausea (n = 2), increased serum creatinine... 

Observational studies The safety and efficacy of zonisamide for intractable focal epilepsy were investigated in 121 Korean patients taking a dose of 200 mg/day. The most common adverse events were dizziness (28.1%), somnolence (24.0%), anorexia (18.2%), headache (14%), nausea (13.2%), and weight loss (10.7%) [203 ]. 

Placebo-controlled studies A study of zonisamide for weight loss randomized participants to receive zonisamide 200 mg/day, 400 mg/day, or placebo [204 ]. Altered taste, constipation, diarrhea, dry mouth, headache, fatigue, nausea/vomiting, somnolence, language and speech problems, impaired attention or concentration, memory problems, anxiety, and depression were more common with one or both of the zonisamide doses when compared to placebo. 

---